Related Experiment Video
Updated: Jun 13, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA
Paras Kumar Mishra1, Naira Metreveli, Suresh C Tyagi
1Department of Physiology & Biophysics, School of Medicine, University of Louisville, HSC -A -1215, 500S Preston Street, Louisville, KY 40202, USA. pkmish01@louisville.edu
Abstract:
Although matrix metalloproteinase-9 (MMP-9) is involved in cardiomyocytes contractility dysfunction, tissue inhibitor of metalloproteinase-4 (TIMP-4) mitigates the effect of MMP-9, and proteinase-activated receptor-1 (PAR-1, a G-protein couple receptor, GPCR) is involved in the signaling cascade of MMP-9-mediated cardiac dysfunction, the mechanism(s) are unclear. To test the hypothesis that induction of dicer and differential expression of microRNAs (miRNAs) contribute, in part, to the down regulation of sarcoplasmic reticulum calcium ATPase isoform 2a (serca-2a) in MMP-9 and PAR-1-mediated myocytes dysfunction, ventricular cardiomyocytes were isolated from C57BL/6J mice and treated with 3 ng/ml of MMP-9, 12 ng/ml of TIMP-4, and 10 and 100 microM of PAR-1 antagonist with MMP-9. Specific role of MMP-9 was determined by using MMP-9 knock out (MMP-9KO) and their corresponding control (FVB) mice. Ion Optics video-edge detection system and Fura 2-AM loading were used for determining the contractility and calcium release from cardiomyocytes. Quantitative and semi-quantitative PCR were used to determine the expression of dicer, TIMP-4 and serca-2a. miRNA microarrays were used for assessing the expression of different miRNAs between MMP-9KO and FVB cardiomyocytes. The results suggest that MMP-9 treatment attenuates the voltage-induced contraction of primary cardiomyocytes while TIMP-4, an inhibitor of MMP-9, reverses the inhibition. MMP-9 treatment is also associated with reduced Ca(2+) transients. This effect is blocked by a PAR-1 antagonist, suggesting that PAR-1 mediates this effect. The effect is not as great at high concentrations (100 microM) perhaps due to mild toxicity. The PAR-1 antagonist effect did not affect calcium transients unlike TIMP-4. Interestingly, we show that MMP-KO myocytes contract more rapidly and release more Ca(2+) than FVB. The relevant RNA species serca-2a is induced and dicer is inhibited. There is selective inhibition of miR-376b and over-expression of miR-1, miR-26a, miR-30d, and miR-181c in MMP-9KO that are implicated in regulation of G-PCR and calcium handling.
Insights
Matrix metalloproteinase-9 (MMP-9) impairs cardiomyocyte function via proteinase-activated receptor-1 (PAR-1), but microRNAs and dicer influence sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) expression, impacting cardiac contractility.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Biochemistry
Background:
- Matrix metalloproteinase-9 (MMP-9) contributes to cardiomyocyte dysfunction.
- Tissue inhibitor of metalloproteinase-4 (TIMP-4) can mitigate MMP-9 effects.
- Proteinase-activated receptor-1 (PAR-1) signaling is implicated in MMP-9-induced cardiac issues, but mechanisms remain unclear.
Purpose of the Study:
- To investigate if dicer induction and microRNA (miRNA) dysregulation contribute to sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a) downregulation in MMP-9 and PAR-1-mediated cardiomyocyte dysfunction.
- To elucidate the roles of MMP-9, TIMP-4, and PAR-1 in regulating cardiomyocyte contractility and calcium handling.
Main Methods:
- Isolated ventricular cardiomyocytes from C57BL/6J mice and MMP-9 knockout (MMP-9KO) mice.
- Treatment with MMP-9, TIMP-4, and PAR-1 antagonist.
- Assessment of cardiomyocyte contractility and calcium transients using Ion Optics video-edge detection and Fura 2-AM.
- Quantitative PCR for dicer, TIMP-4, and SERCA2a expression.
- miRNA microarrays to compare expression profiles between MMP-9KO and control cardiomyocytes.
Main Results:
- MMP-9 treatment reduced cardiomyocyte contraction and Ca(2+) transients, an effect blocked by PAR-1 antagonist.
- TIMP-4 reversed MMP-9-induced inhibition of contraction and Ca(2+) transients.
- MMP-9 knockout (MMP-9KO) cardiomyocytes exhibited enhanced contractility and Ca(2+) release compared to controls.
- SERCA2a expression was upregulated, and dicer expression was inhibited in MMP-9KO myocytes.
- Selective miRNA changes observed in MMP-9KO myocytes, including inhibition of miR-376b and overexpression of miR-1, miR-26a, miR-30d, and miR-181c.
Conclusions:
- MMP-9 impairs cardiomyocyte function, partly mediated by PAR-1 signaling.
- TIMP-4 acts as a protective factor against MMP-9-induced cardiac dysfunction.
- Dicer and specific miRNAs play a role in regulating SERCA2a expression and cardiomyocyte calcium handling in response to MMP-9.
- These findings reveal novel molecular mechanisms underlying MMP-9-related cardiac dysfunction involving miRNA-mediated regulation of SERCA2a.
Related Concept Videos
Experimental RNAi
MicroRNAs
MicroRNAs
Abnormal Proliferation